Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
Hauser SL, Giovannoni G, Montalban X, Oh J, Bar-Or A, Sormani M P, Weber MS, Stoll S, Nicholas JA, Nehrych T, et al.
Lancet. 2026 May 30; 407(10544):2180-2194. PMID: 42208560.Abstract
